| EFNB3 - Ephrin B3 | |
|---|---|
| Gene Symbol | EFNB3 |
| Full Name | Ephrin B3 |
| Chromosome | 19p13.3 |
| NCBI Gene ID | [1949](https://www.ncbi.nlm.nih.gov/gene/1949) |
| OMIM | [601168](https://www.omim.org/entry/601168) |
| Ensembl ID | [ENSG00000108947](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108947) |
| UniProt ID | [Q99968](https://www.uniprot.org/uniprotkb/Q99968/entry) |
| Protein Class | Ephrin (transmembrane) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Neurodevelopmental Disorders |
EFNB3 (Ephrin B3) is a transmembrane ligand for EPH (Erythropoietin-producing hepatocyte) receptors that mediates bidirectional cell-cell communication critical for neural development, synaptic plasticity, and cellular signaling[^efnb3_neuronal_2020]. As a member of the ephrin-B family (EFNB1, EFNB2, EFNB3), EFNB3 plays crucial roles in nervous system development and function, with emerging evidence linking its dysregulation to neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[^efnb3_eph_signaling_2019].
Unlike secreted growth factors, ephrin proteins are membrane-anchored, enabling direct cell-cell contact signaling. This unique presentation allows EFNB3 to mediate precise spatial signaling events during development and in the adult brain.
EFNB3 is a 341-amino acid transmembrane protein with distinctive domains:
N-terminal ephrin domain (extracellular): The receptor-binding region
Transmembrane domain: Single pass α-helix
C-terminal cytoplasmic domain:
EFNB3 signals through two primary mechanisms:
When EFNB3 binds to EPHB receptors on adjacent cells:
The cytoplasmic domain transduces signals:
EFNB3 primarily interacts with:
| Receptor | Expression | Function |
|---|---|---|
| EPHB1 | Brain, marrow | Synaptic development |
| EPHB2 | Brain (hippocampus) | Synaptic plasticity, memory |
| EPHB3 | Developing brain | Axon guidance |
| EPHB4 | Vascular, brain | Angiogenesis |
EFNB3 has emerged as a potential therapeutic target in AD[^efnb3_alzheimers_2021]:
In PD, EFNB3 may contribute through[^efnb3_parkinsons]:
EFNB3 has been implicated in:
EFNB3 exhibits tissue-specific expression:
| Region | Expression Level | Notes |
|---|---|---|
| Brain | High | Hippocampus, cortex, cerebellum |
| Developing CNS | Very high | Peak during development |
| Peripheral tissues | Moderate | Vascular, mesenchymal |
| Adult brain | Moderate | Synaptic compartments |
In the brain, EFNB3 is expressed in:
EFNB3 critically regulates[efnb3_synapse][efnb3_plasticity]:
During development, EFNB3[^efnb3_guidance]:
In the mature brain, EFNB3:
EFNB3 interacts with multiple AD/PD genes:
| Gene | Interaction Type |
|---|---|
| APOE | Shared lipid signaling pathways |
| SNCA | Synaptic function interplay |
| LRRK2 | Phosphorylation pathways |
| BDNF | Synaptic plasticity convergence |
Targeting EFNB3 signaling offers therapeutic potential[^efnb3_therapeutic]:
Agonists:
Antagonists:
Potential therapeutic areas:
| Protein | Primary Receptors | Key Functions |
|---|---|---|
| EFNA1 | EPHA2, EPHA4 | Vascular development |
| EFNA2 | EPHA1, EPHA4 | Neuronal function |
| EFNA3 | EPHA3, EPHA5 | Axon guidance |
| EFNA4 | EPHA2, EPHA7 | Vascular |
| EFNB1 | EPHB1, EPHB2 | Synaptic function |
| EFNB2 | EPHB2, EPHB3 | Development, plasticity |
| EFNB3 | EPHB2, EPHB3 | Forebrain, synapses |
EFNB3 shows evolutionary conservation:
| Species | Homolog | Conservation |
|---|---|---|
| Human | EFNB3 | Reference |
| Mouse | Efnb3 | 95% identical |
| Zebrafish | efnb3 | 85% identical |
| Chick | EFNB3 | 92% identical |
| Xenopus | efnb3 | 80% identical |
EFNB3 plays critical roles in assembling and maintaining neural circuits[@efnb3_circuit]. During development, EFNB3 contributes to formation of specific axonal tracts, establishment of topographic maps, development of cortical columns, and formation of hippocampal circuitry. In the adult brain, EFNB3 continues to support synaptic connectivity maintenance, activity-dependent plasticity, circuit stability and refinement, and experience-dependent reorganization. Impaired EFNB3 signaling contributes to circuit dysfunction through disrupted connectivity patterns in AD, aberrant circuit activity in PD, and network-level impairments in neurodegeneration.
Ephrin signaling mediates astrocyte-neuron interactions[@efnb3_astrocyte]. Astrocytes and neurons communicate via EFNB3-EPHB signaling where astrocytic EFNB3 activates neuronal EPHB receptors, reverse signaling into astrocytes modulates function, forming bidirectional communication channels. EFNB3 signaling affects metabolic support by modulating astrocytic glucose uptake, regulating lactate shuttle to neurons, and supporting neuronal energy demands. Astrocytic EFNB3 influences calcium dynamics by affecting astrocyte calcium waves, modulating neuron-astrocyte signaling, and impacting neurovascular coupling.
Microglial cells express ephrin receptors and respond to EFNB3[@efnb3_microglia]. EFNB3 modulates microglial phenotypes by influencing M1/M2 polarization, affecting cytokine production, and modulating phagocytic activity. During development and in disease, EPHB receptors mediate synaptic elimination, microglial EFNB3 affects developmental pruning, and dysregulation contributes to synapse loss in neurodegeneration. EFNB3 signaling in neuroinflammation modulates microglial responses to injury, affects neuroinflammation chronicity, and represents a potential therapeutic target for neuroinflammatory conditions.
EFNB3 intersects with tau pathology[@efnb3_tau]. Ephrin signaling influences tau kinases where EPHB activation affects GSK-3β activity, modulates CDK5 signaling, and alters tau phosphorylation state. Potential roles in tau propagation include effects on tau release, influence on uptake of pathological tau, and contribution to spreading pathology. Targeting EFNB3-EPHB signaling may reduce tau phosphorylation, decrease tau spread, and protect against tau-induced synaptic damage.
In Parkinson's disease, ephrins interact with alpha-synuclein[@efnb3_alpha]. EFNB3 signaling may affect alpha-synuclein by modulating aggregation propensity, influencing oligomer formation, and affecting fibrilization kinetics. Dopaminergic neurons show particular vulnerability due to EPHB receptor expression patterns, EFNB3-mediated survival signaling, and intersection with PD genetic factors. Potential connections to Lewy body pathology include effects on autophagy-lysosome pathway, modulation of protein clearance, and interactions with ubiquitin-proteasome system.
EFNB3 undergoes functional transitions[@efnb3_development_adult]. During development, EFNB3 shows high expression in embryonic brain, spatiotemporal regulation of isoforms, and critical periods for EFNB3-dependent development. Adult expression differs from development with lower overall expression, synaptic localization, and activity-dependent regulation. The developmental-to-adult transition involves changes in receptor expression, alterations in downstream signaling, and shift from developmental to maintenance functions.
New therapeutic strategies target ephrin signaling[@efnb3_therapeutic_2024]. Soluble ephrin domains and fusion proteins include EPHB2-Fc agonists in development, EFNB3-Fc for synaptic enhancement, and combined receptor agonists. Blocking pathological signaling involves soluble EPH receptors as decoys, small molecule kinase inhibitors, and blocking peptides. Key hurdles for clinical translation include blood-brain barrier penetration, receptor selectivity, temporal targeting, and avoiding developmental effects.
Ephrin signaling affects the neurovascular unit[@efnb3_vasculature]. EFNB3 modulates blood vessel formation where EPHB4/EFNB2 is involved in venous angiogenesis, EFNB3 in arterial specification, and vessel maturation and stabilization. BBB function involves ephrin signaling through tight junction regulation, transport mechanisms, and endothelial cell maintenance. EFNB3 contributes to functional hyperemia through astrocyte-endothelial communication, vasodilatory responses to neural activity, and implications for neurodegenerative disease.
Aging alters EFNB3 expression and function[@efnb3_aging]. Age-related changes include reduced EFNB3 expression in hippocampus, altered isoform ratios, and decreased synaptic localization. Expression changes affect synaptic plasticity deficits, impaired circuit function, and reduced resilience to stress. Potential approaches to restore EFNB3 include exercise and environmental enrichment, gene therapy for EFNB3 expression, and small molecule modulation.